|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019196,
umls-concept:C0019699,
umls-concept:C0030705,
umls-concept:C0040808,
umls-concept:C0079399,
umls-concept:C0205054,
umls-concept:C0205082,
umls-concept:C0332281,
umls-concept:C0441471,
umls-concept:C0750480,
umls-concept:C0936012,
umls-concept:C1332714
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-11-26
|
|
pubmed:abstractText |
Nevirapine-containing regimens have been associated with a risk of significant elevations of liver transaminase levels. Higher risk in antiretroviral-naive populations has been related to gender and CD4+ T-cell count (women with CD4+ T-cell counts of > or =250/mm(3) or men with CD4+ T-cell counts of > or =400/mm(3), i.e. group at risk). However, recent studies do not confirm this association in HIV populations comprising patients who are antiretroviral-experienced. Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0114-5916
|
|
pubmed:author |
pubmed-author:BHCC Study Group,
pubmed-author:CarosiGiampieroG,
pubmed-author:CastelnuovoFilippoF,
pubmed-author:CologniGiulianaG,
pubmed-author:CostarelliSilviaS,
pubmed-author:De SilvestriAnnalisaA,
pubmed-author:LapadulaGiuseppeG,
pubmed-author:ParaninfoGiuseppeG,
pubmed-author:PuotiMassimoM,
pubmed-author:Quiros-RoldanEugeniaE,
pubmed-author:TortiCarloC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1161-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18035868-Adult,
pubmed-meshheading:18035868-Alanine Transaminase,
pubmed-meshheading:18035868-Anti-HIV Agents,
pubmed-meshheading:18035868-Aspartate Aminotransferases,
pubmed-meshheading:18035868-CD4 Lymphocyte Count,
pubmed-meshheading:18035868-Cohort Studies,
pubmed-meshheading:18035868-Drug Therapy, Combination,
pubmed-meshheading:18035868-Drug-Induced Liver Injury,
pubmed-meshheading:18035868-Female,
pubmed-meshheading:18035868-HIV Infections,
pubmed-meshheading:18035868-HIV-1,
pubmed-meshheading:18035868-Hepacivirus,
pubmed-meshheading:18035868-Hepatitis C,
pubmed-meshheading:18035868-Hepatitis C Antibodies,
pubmed-meshheading:18035868-Humans,
pubmed-meshheading:18035868-Liver,
pubmed-meshheading:18035868-Liver Function Tests,
pubmed-meshheading:18035868-Male,
pubmed-meshheading:18035868-Nevirapine,
pubmed-meshheading:18035868-Retrospective Studies,
pubmed-meshheading:18035868-Reverse Transcriptase Inhibitors,
pubmed-meshheading:18035868-Risk Factors,
pubmed-meshheading:18035868-Sex Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
|
|
pubmed:affiliation |
School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. torti.carlo@libero.it
|
|
pubmed:publicationType |
Journal Article
|
